Incyte Corporation I1NC34.SA Stock
Incyte Corporation Price Chart
Incyte Corporation I1NC34.SA Financial and Trading Overview
Incyte Corporation stock price | 144.9 BRL |
Previous Close | 150.6 BRL |
Open | 0 BRL |
Bid | 149.55 BRL x N/A |
Ask | 150.37 BRL x N/A |
Day's Range | 0 - 0 BRL |
52 Week Range | 0 - 218.46 BRL |
Volume | 0 BRL |
Avg. Volume | 83 BRL |
Market Cap | 67.19B BRL |
Beta (5Y Monthly) | 0.715845 |
PE Ratio (TTM) | 42.542374 |
EPS (TTM) | 6.75 BRL |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
I1NC34.SA Valuation Measures
Enterprise Value | 64.12B BRL |
Trailing P/E | 42.542374 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 19.363716 |
Price/Book (mrq) | 15.055484 |
Enterprise Value/Revenue | 18.478 |
Enterprise Value/EBITDA | 111.38 |
Trading Information
Incyte Corporation Stock Price History
Beta (5Y Monthly) | 0.715845 |
52-Week Change | -20.26% |
S&P500 52-Week Change | 20.43% |
52 Week High | 218.46 BRL |
52 Week Low | 0 BRL |
50-Day Moving Average | 171.13 BRL |
200-Day Moving Average | 189.61 BRL |
I1NC34.SA Share Statistics
Avg. Volume (3 month) | 83 BRL |
Avg. Daily Volume (10-Days) | 255 BRL |
Shares Outstanding | 446.17M |
Float | 371.38M |
Short Ratio | N/A |
% Held by Insiders | 0% |
% Held by Institutions | 0.0040% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 9.34% |
Operating Margin (ttm) | 14.46% |
Gross Margin | 47.86% |
EBITDA Margin | 16.58% |
Management Effectiveness
Return on Assets (ttm) | 5.78% |
Return on Equity (ttm) | 7.79% |
Income Statement
Revenue (ttm) | 3.47B BRL |
Revenue Per Share (ttm) | 7.8 BRL |
Quarterly Revenue Growth (yoy) | 10.29% |
Gross Profit (ttm) | 1.59B BRL |
EBITDA | 575.7M BRL |
Net Income Avi to Common (ttm) | 324.37M BRL |
Diluted EPS (ttm) | 3.54 |
Quarterly Earnings Growth (yoy) | -42.89% |
Balance Sheet
Total Cash (mrq) | 3.11B BRL |
Total Cash Per Share (mrq) | 6.98 BRL |
Total Debt (mrq) | 40.24M BRL |
Total Debt/Equity (mrq) | 0.9 BRL |
Current Ratio (mrq) | 3.948 |
Book Value Per Share (mrq) | 10.003 |
Cash Flow Statement
Operating Cash Flow (ttm) | 648.6M BRL |
Levered Free Cash Flow (ttm) | 522.97M BRL |
Profile of Incyte Corporation
Country | Brazil |
State | DE |
City | Wilmington |
Address | 1801 Augustine Cut-Off |
ZIP | 19803 |
Phone | 302 498 6700 |
Website | https://www.incyte.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 2324 |
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States, Europe, Japan, and internationally. The company offers JAKAFI (ruxolitinib), for the treatment of adults with intermediate or high-risk myelofibrosis; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab), for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed as a therapy for patients with chronic GVHD as well as in additional immune-mediated diseases; and parsaclisib, a PI3Kd inhibitor which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. It also develops retifanlimab, is in Phase III clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer, and Fast Track designation for the treatment of metastatic MSI-H or DNA mismatch repair (dMMR) endometrial cancer; and INCB99280 and INCB99318 currently under Phase I for the treatment solid tumors. It has collaboration out- license agreements with Novartis, Lilly, Innovent, InnoCare, Maruho, and CMS Aesthetics Limited; and in- license agreements with Agenus, Merus, MacroGenics, Syros, MorphoSys, and Syndax. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Q&A For Incyte Corporation Stock
What is a current I1NC34.SA stock price?
Incyte Corporation I1NC34.SA stock price today per share is 144.9 BRL.
How to purchase Incyte Corporation stock?
You can buy I1NC34.SA shares on the São Paulo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Incyte Corporation?
The stock symbol or ticker of Incyte Corporation is I1NC34.SA.
Which industry does the Incyte Corporation company belong to?
The Incyte Corporation industry is Biotechnology.
How many shares does Incyte Corporation have in circulation?
The max supply of Incyte Corporation shares is 449.05M.
What is Incyte Corporation Price to Earnings Ratio (PE Ratio)?
Incyte Corporation PE Ratio is 21.46666500 now.
What was Incyte Corporation earnings per share over the trailing 12 months (TTM)?
Incyte Corporation EPS is 6.75 BRL over the trailing 12 months.
Which sector does the Incyte Corporation company belong to?
The Incyte Corporation sector is Healthcare.